Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Tulln An Der Donau – page 72

881 clinical trials in Tulln An Der Donau, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Tulln An Der Donau at a glance
881
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

881 trials in Tulln An Der Donau

Open in trial search

Macular oedema+1

Not recruiting

Study on the Effectiveness and Safety of Aflibercept for Patients with Vision Loss Due to Macular Edema from Retinal Vein Blockage

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Bayer AG

Study on ALLO-647 and ALLO-501A for Adults with Relapsed or Refractory Large B-Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ALLO-501A
  • Sponsor:Allogene Therapeutics Inc.

Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Kite Pharma Inc.

Study Comparing Nivolumab and Ipilimumab with Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol Myers Squibb International Corporation

Status epilepticus

Not recruiting

Study on Ganaxolone for Patients with Refractory Status Epilepticus

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ganaxolone
  • Sponsor:Marinus Pharmaceuticals Inc.

Study Comparing Patritumab Deruxtecan and Platinum-based Chemotherapy for Patients with Advanced EGFR-mutated Non-small Cell Lung Cancer After EGFR Therapy Failure

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Study on Carfilzomib and Ibrutinib for Patients with Waldenström’s Macroglobulinemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Universitaetsklinikum Ulm AöR

Study on the Safety of Avacincaptad Pegol for Patients with Geographic Atrophy Who Completed a Previous Study

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Avacincaptad Pegol
  • Sponsor:Astellas Pharma Global Development Inc.

Study of Tarlatamab Treatment for Patients with Small Cell Lung Cancer Who Have Not Responded to Two or More Previous Treatments

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Plasma cell myeloma

Not recruiting

Study of Isatuximab with Lenalidomide and Dexamethasone for Elderly Patients (70+) with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Isatuximab
  • Sponsor:Arbeitsgemeinschaft Medikamentoese Tumortherapie gGmbH

Study on Norucholic Acid for Treating Primary Sclerosing Cholangitis in Patients

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Norucholic Acid
  • Sponsor:Dr. Falk Pharma GmbH

Transplant rejection

Not recruiting

Study on Efgartigimod for Patients with Antibody-Mediated Rejection after Kidney Transplant

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Tulln An Der Donau

What the registry says about research in the country

01 Neurological Disorders

Research focusing on Multiple System Atrophy and its associated conditions, particularly investigating new therapeutic approaches for managing neurogenic orthostatic hypotension. Studies aim to evaluate novel treatments for improving patient symptoms and quality of life.

  • Orthostatic Hypotension Management
  • Autonomic Nervous System Disorders
  • Symptomatic Treatment Evaluation

Current trials are examining long-term effectiveness and durability of new therapeutic interventions.

02 Neuropathic Pain Studies

Comprehensive research into various forms of chronic neuropathic pain, including diabetic polyneuropathy and post-operative peripheral neuropathy. Studies are evaluating new therapeutic options for patients with treatment-resistant conditions.

  • Diabetic Polyneuropathy
  • Traumatic Neuropathy
  • Central Neuropathy

Investigations focus on add-on treatments to enhance current pain management protocols.

03 Chronic Pain Management

Innovative research targeting chronic back pain and various pain conditions, evaluating new therapeutic approaches for improved patient outcomes. Studies are designed to assess both efficacy and tolerability of novel treatment options.

  • Back Pain Treatment
  • Pain Management Protocols
  • Treatment Tolerability Assessment

Current research emphasizes developing comprehensive pain management solutions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.